The incidence of thyroid disease in children with alopecia areata (AA) has been widely studied with no consensus on whether a true association with AA exists. In addition, screening practices for thyroid dysfunction in children with AA vary widely among clinicians.
A lopecia areata (AA) is a nonscarring type of hair loss with a lifetime risk of about 1% to 2% of the general US population. 1 In conjunction with genetic predisposition and environmental triggers, autoimmunity plays a key role in AA. 2 Alopecia areata has been linked to multiple other autoimmune diseases, with vitiligo and thyroid disorders displaying the strongest association. 3 Prevalence of thyroid disease varies with a reported range from 8% to 28% and no clear relation to AA type, severity, or family medical history. 4 Though screening practices differ significantly among clinicians, many patients with AA will receive a workup for thyroid dysfunction, including thyrotropin (formerly thyroid stimulating hormone [TSH]), free thyroxine (FT4), as well as an assessment for elevated thyroid autoantibodies. However, the results of these tests have questionable utility because abnormal values in TSH, thyroid peroxidase antibodies (TPO-Abs), and thyroglobulin antibodies (Tg-Abs) have been found in up to 15%, 11%, and 10%, respectively, of healthy individuals without further clinical sequela. 5 The aim of this study was to characterize thyroid function in patients with AA to establish guidelines for screening.
Methods
We conducted a retrospective medical chart review of all patients seen at the Children's Hospital of Philadelphia between January 2008 and January 2016 with a diagnosis of alopecia areata. Only patients who had thyroid function testing were part of the final analysis. Testing included TSH, FT4, triiodothyronine (T3), TPO-Abs, and Tg-Abs. Information regarding age at first visit, sex, past medical history, and family medical history were recorded. Characteristics of AA including location and type were documented as well as results of thyroid function tests. The severity of AA was defined according to the investigational guidelines described by Olsen et al 6 : mild when there was less than 25% hair loss, moderate for 26% to 50% hair loss, and extensive for more than 50% hair loss. Cut-offs for abnormal thyroid results were defined by the American Thyroid Association Task Force guidelines. 7 Subclinical hypothyroidism was diagnosed if serum TSH levels were above 4.5 mIU/L, but below 10mIU/L with normal T4 and T3 levels, while overt hypothyroidism also required a low T4 and T3 value. 8 Descriptive and multivariable analyses were performed using SPSS statistical software (version 19.0, IBM) with P < .05 deemed statistically significant. The Children's Hospital of Philadelphia institutional review board approved this study and informed consent was waived. (12 [20%] ) and subclinical thyroid dysfunction (7 [12%] ). Whereas age, duration of disease, pattern of alopecia, and diagnosis of autoimmune diseases had no significant association with abnormal thyroid findings, a personal medical history of Down syndrome, atopy, and family medical history of thyroid disease did ( Table 1 and Table 2 ). Based on these results, we created suggested screening guidelines for thyroid disease in patients presenting with AA (Box).
Results

During
Discussion
Multiple comorbid conditions have been reported in patients with AA, including atopy and autoimmune diseases. In particular, the incidence of thyroid disease has been widely studied with no consensus on whether a true association with AA exists and universal screening for thyroid dysfunction is worthwhile. In addition, guidelines for standardized treatment of patients found to have subclinical thyroid dysfunction associated with AA do not exist.
Though our study is limited by its retrospective design and single-center site, our results demonstrate statistically significant association of Down syndrome (P = .004), atopy (P = .009), and family medical history of thyroid disease (P = .001) in patients with AA who have increased incidence of thyroid abnormalities. Alopecia areata commonly occurs in patients with Down syndrome, with up to 9% of the population affected. 9 Moreover, autoimmune diseases and especially thyroid disease have a higher prevalence and incidence in patients with Down syndrome. 10 Atopy has similarly been associated with increased risk and severity of AA. 11 It has been suggested that the dysfunction of
Key Points
Question Do children with alopecia areata (AA) require thyroid function screening tests?
Findings In this retrospective review of 298 children with AA, we found a history of Down syndrome, atopy, and family history of thyroid disease had significant association with incidence of thyroid abnormalities. Age at diagnosis, duration of disease, and pattern of AA had no significant association.
Meaning Thyroid function screening should be restricted to AA patients with a medical history of Down syndrome, personal history of atopy, a family history of thyroid disease, or clinical findings suggestive of potential thyroid dysfunction in the individual patient.
T regulatory cells present in atopic patients may contribute to the development of autoimmune diseases such as AA and thyroid disease. 12 The presence of these clinical features in patients with AA is thus a good indication for further work-up, including assessment of thyroid function.
We suggest that in patients with either a personal history of Down syndrome, personal medical history of atopy, or a family medical history of thyroid disease, a thyroid screening with TSH and free T4 should be ordered at first presentation. If abnormalities are detected in either of these values, we then recommend ordering antibody (TPO-Abs or Tg-Abs) tests for potential autoimmune causes of thyroid dysfunction. In all other patients with AA, unless there are concerning features on physical examination, such as goiter, or in the patient's medical history, such as deviation on the growth chart, fatigue, or constipation, we propose that routine thyroid screening should not be performed. Of note, for patients on biotin for the reported benefit in hair and nail strength, laboratory results may be falsely elevated in competitive assays (free T4, total T3) or falsely decreased in noncompetitive assays (TSH) because most immunoassays rely on biotinstreptavidin interactions to anchor antibodies. 13 For patients taking biotin supplementation, the biotin should be discontinued for 48 to 72 hours prior to the laboratory draw to avoid potential biotin-associated alterations in assay results.
In the present study, we did not analyze the relationship between levels of T3 and AA. Most patients with hypothyroidism are assumed to benefit from medications that act to replenish T4 levels because this is later converted to the active T3 in the body through type 1 and 2 deiodinase activity. However, some patients with inflammatory conditions and specifically autoimmune diseases have been found to have decreased deiodinase activity, leaving them with decreased efficiency in converting T4 to the more active T3.
14 Thyroid hormones are known to play a significant role in the regulation of stem cells located in the bulge region of hair follicle and aid in hair cycling. 15 Future studies should further investigate the potential role of T3 to ensure that AA patients with thyroid dysfunction are receiving appropriate treatment.
Limitations
The study is limited by its retrospective design and its reliance on electronic medical records. In addition, our participants were drawn from a single-center tertiary-care hospital which may limit generalizability.
Conclusions
To reduce health care costs, eliminate unnecessary testing, and standardize clinical practices, we recommend that routine thyroid function screening should be restricted to patients with AA who have a personal medical history of Down syndrome, personal medical history of atopy, a family history of thyroid disease, or clinical findings (goiter) suggestive of potential thyroid dysfunction in the individual patient.
